Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

BACKGROUND: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab. METHODS: The study was divided into two parts; parts A...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkinson, Victoria, Khattak, Adnan, Haydon, Andrew, Eastgate, Melissa, Roy, Amitesh, Prithviraj, Prashanth, Mueller, Christian, Brignone, Chrystelle, Triebel, Frederic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682474/
https://www.ncbi.nlm.nih.gov/pubmed/33219094
http://dx.doi.org/10.1136/jitc-2020-001681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682474/
https://www.ncbi.nlm.nih.gov/pubmed/33219094
http://dx.doi.org/10.1136/jitc-2020-001681

Ejemplares similares